✦ LIBER ✦

High expression of cereblon ( CRBN ) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone

✍ Scribed by Heintel, Daniel; Rocci, Alberto; Ludwig, Heinz; Bolomsky, Arnold; Caltagirone, Simona; Schreder, Martin; Pfeifer, Sabine; Gisslinger, Heinz; Zojer, Niklas; Jäger, Ulrich; Palumbo, Antonio

Book ID: 120409727
Publisher: John Wiley and Sons
Year: 2013
Tongue: English
Weight: 209 KB
Volume: 161
Category: Article
ISSN: 0007-1048
DOI: 10.1111/bjh.12338

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effects of Lenalidomide and Dexamethason

Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone

✍ Jesús F. San-Miguel; Meletios A. Dimopoulos; Edward A. Stadtmauer; S. Vincent Ra 📂 Article 📅 2011 🏛 Elsevier 🌐 English ⚖ 208 KB

Effective prophylaxis of thromboembolic

Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone

✍ Ulrike Klein; Florentina Kosely; Jens Hillengaß; Michael Hundemer; Stefan Schmit 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 107 KB

Impact of high-risk cytogenetics and pri

Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone

✍ Avet-Loiseau, H; Soulier, J; Fermand, J-P; Yakoub-Agha, I; Attal, M; Hulin, C; G 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 313 KB

The potential benefits of participating

The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib

✍ Paul G. Richardson; Jacob P. Laubach; Robert L. Schlossman; Irene M. Ghobrial; K 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB

Bortezomib is associated with better hea

Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study

✍ Stephanie J. Lee; Paul G. Richardson; Pieter Sonneveld; Michael W. Schuster; Dav 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 136 KB

Low dose lenalidomide induction followed

Low dose lenalidomide induction followed by autologous transplantation in untreated patients with myeloma is associated with adequate collection of haematopoietic and dendritic cell precursors and high response rates

✍ Khot, A.; Sedunary, R.; Stokes, K.; Loudovaris, M.; Wall, D.; Prince, M.; Ritchi 📂 Article 📅 2013 🏛 Informa plc 🌐 English ⚖ 73 KB